Patient characteristics, clinical outcomes, and effect of dapagliflozin in relation to duration of heart failure: is it ever too late to start a new therapy?
SE Yeoh, P Dewan, PS Jhund, SE Inzucchi… - … : Heart Failure, 2020 - Am Heart Assoc
… ejection fraction (LVEF) ≤40%, an elevated natriuretic peptide level and were receiving
optimal HFrEF pharmacological and device therapy, according to local guidelines. …
optimal HFrEF pharmacological and device therapy, according to local guidelines. …
Effect of dapagliflozin on indicators of myocardial fibrosis and levels of inflammatory factors in heart failure patients
C Wang, Y Qin, X Zhang, Y Yang, X Wu, J Liu… - Disease …, 2022 - Wiley Online Library
… b-type natriuretic peptide (BNP) were detected in the department of laboratory. The level
of monocyte chemoattractant protein-1 (MCP-1) in serum was detected using enzyme-linked …
of monocyte chemoattractant protein-1 (MCP-1) in serum was detected using enzyme-linked …
Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of …
RA Scholtes, MHA Muskiet, MJB van Baar… - Diabetes …, 2021 - Am Diabetes Assoc
… N-terminal pro-B-type natriuretic peptide (NT-proBNP) were … with dapagliflozin in patients
who had no heart failure or … volume observed in a prior study with dapagliflozin (12). In addition…
who had no heart failure or … volume observed in a prior study with dapagliflozin (12). In addition…
Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria–A double blind randomized placebo-controlled crossover trial
MK Eickhoff, FJ Olsen, M Frimodt-Møller, LJ Diaz… - Journal of Diabetes and …, 2020 - Elsevier
… of heart failure (HF) and cardiovascular death in people with type 2 diabetes (T2D) and …
cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac …
cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac …
… in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and …
X Wang, M Vaduganathan, BL Claggett, SM Hegde… - Circulation, 2023 - Am Heart Assoc
… ≥40 years of age with chronic NYHA class II to IV HF, LVEF >40%, structural heart disease
(… in natriuretic peptides. In both trials, patients were randomized to receive dapagliflozin 10 …
(… in natriuretic peptides. In both trials, patients were randomized to receive dapagliflozin 10 …
Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial
… %, evidence of structural heart disease (either left atrial enlargement or left ventricular
hypertrophy), and NT-proBNP (N-terminal pro–B-type natriuretic peptide) concentration ≥300 pg/…
hypertrophy), and NT-proBNP (N-terminal pro–B-type natriuretic peptide) concentration ≥300 pg/…
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status
A Peikert, P Goyal, M Vaduganathan, BL Claggett… - Heart Failure, 2023 - jacc.org
… >40%, elevated N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels (≥300 pg/mL …
structural heart disease (left atrial enlargement or left ventricular hypertrophy). Patients with …
structural heart disease (left atrial enlargement or left ventricular hypertrophy). Patients with …
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
NMA Idzerda, BV Stefansson, MJ Pena… - Nephrology Dialysis …, 2020 - academic.oup.com
… For example, we ideally would have used N-terminal prohormone of brain natriuretic peptide
as a marker for volume status instead of body weight, as the latter may merely represent …
as a marker for volume status instead of body weight, as the latter may merely represent …
[HTML][HTML] Natriuretic Peptide–Based Risk Prediction and Assessment of Treatment Effect: Revisited in This Era
A Tanaka, K Node - Heart Failure, 2021 - jacc.org
… Natriuretic peptide (NP) levels, such as those of N-terminal pro–B-type NP (NT-proBNP), …
of heart failure (HF) and its risk prediction. However, NP values are often modified by cardiac …
of heart failure (HF) and its risk prediction. However, NP values are often modified by cardiac …
Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized …
FR Mc Causland, BL Claggett, M Vaduganathan… - JAMA …, 2023 - jamanetwork.com
… Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. …
ejection fraction greater than 40%, elevated N-terminal pro–brain natriuretic peptide (NT-proBNP) …
ejection fraction greater than 40%, elevated N-terminal pro–brain natriuretic peptide (NT-proBNP) …